Ticker brief
LTRN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
1
crowd 14d
+0.44
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-20 · now +0.36 (−1 bearish … +1 bullish)
Who spoke1
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @beach_trades | C | -0.04 | 8 | +0.45 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-20 | @beach_trades | +0.50 | Lantern Pharma and Starlight announce FDA IND clearance for a planned Phase 1 pediatric CNS cancer trial. | · | tweet ↗ |
| 2026-08-20 | @beach_trades | +0.30 | Briefly highlights LTRN as an AI-enabled pediatric-cancer company. | · | tweet ↗ |
| 2026-08-20 | @beach_trades | +0.20 | States that LTRN applies AI to pediatric cancer. | · | tweet ↗ |
| 2026-08-20 | @beach_trades | +0.55 | Highlights LTRN's AI-oncology niche and FDA rare-pediatric and orphan-drug designations as defensive biotech advantages. | · | tweet ↗ |
| 2026-08-20 | @beach_trades | +0.25 | Groups LTRN, TEM and MRK under a cancer AI-biotech theme | · | tweet ↗ |
| 2026-08-19 | @beach_trades | +0.65 | Promotes LTRN as an AI-cancer biotech with FDA Fast Track and Orphan Designation exposure. | · | tweet ↗ |
| 2026-08-19 | @beach_trades | +0.60 | Suggests LTRN may benefit as the MRK-MRNA AI-cancer space awakens. | · | tweet ↗ |
| 2026-08-19 | @beach_trades | +0.55 | Highlights lagging LTRN while peer AI-biotech names make large moves. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.